High-dose Versus Low-dose Clarithromycin in 1-week Triple Therapy, Including Rabeprazole and Levofloxacin, for Helicobacter pylori Eradication

Journal of Clinical Gastroenterology

Volumn 38, Issue 2, 2004, Pages 110-114

  Cammarota, Giovanni ^a,c   Cianci, Rossella ^a   Cannizzaro, Oreste ^b   Martino, Antonio ^a   Fedeli, Paolo ^a   Lecca, Piera Giuseppina ^a   Di Caro, Simona ^a   Cesaro, Paola ^a   Branca, Giovanna ^a   Gasbarrini, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Madonna della Consolazione Hospital   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Clarithromycin; Helicobacter pylori; Levofloxacin; Rabeprazole; Treatment

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GLOSSITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; BREATH TESTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OFLOXACIN; OMEPRAZOLE; TREATMENT OUTCOME;

EID: 9144228628     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200402000-00005     Document Type: Article

References (37)

1. Lind T, van Zanten SV, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH 1 study. Helicobacter. 1996;1:138-144.
2. Lind T, Megraud F, Unge P, et al. The MACH 2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology. 1999;116:248-253.
3. Pipkin GA, Williamson R, Wood JR. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1998;12:823-837.
4. Van der Hulst RWM, Keller JJ, Rauws EA, et al. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1996;1:6-19.
5. Huang JQ, Hunt RH. Treatment after failure: the problem of "non responders." Gut. 1999;45(Suppl. 1):140-144.
6. Bazzoli F, Zagari RM, Fossi S. Short-term low-dose therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol. 1994;6:773-777.
7. Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole. Aliment Pharmacol Ther. 1999;13:719-729.
8. Hoshiya S, Watanabe K, Tokunaga K, et al. Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. J Gastroenterol. 2000;35:10-14.
9. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167-180.
10. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol. 1998;13:1-12.
11. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:1339-1343.
12. Di Caro S, Zocco AM, Cremonini F, et al. Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol. 2002;14:1309-1312.
13. Di Caro S, Ojetti V, Zocco MA, et al. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2002;16:527-532.
14. Goddard AF, Logan RP. Review article: urea breath tests for detecting Helicobacter pylori. Aliment Pharmacol Ther. 1997;11:641-649.
15. Osato MS, Reddy R, Reddy SG, et al. Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int J Antimicrob Agents. 2001;17:39-44.
16. Monteiro LM, Mégraud F. Microbiological aspects of antibiotic resistant Helicobacter pylori strains. Ital J Gastroenterol Hepatol. 1998;30(Suppl. 3):S329-S333.
17. Wayne PA. In: National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. (Supl. 12):M100-S12.
18. Kalach N, Bergeret M, Benhamou PH, et al. High levels of resistance to metronidazole and clarythromycin in Helicobacter pylori strains in children. J Clin Microbiol. 2001;39:394-397.
19. de Boer WA, Thys JC, Borody TJ, et al. Proposal for use of a standard side effect scoring system in studies exploring treatment regimens. Eur J Gastroenterol Hepatol. 1996;8:641-643.
20. Goh KL. Update on indications for treatment of Helicobacter pylori (including Maastricht 2.). Curr Opin Gastroenterol. 2001;17(Suppl. 1):S43-S46.
21. Kato M, Yamaoka Y, Kim JJ, et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother. 2000;44:2214-2216.
22. Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther. 1997;11:43-53.
23. Vakil N, Hahn B, McSrley D. Clarithromycin resistant Helicobacter pylori in patients with duodenal ulcer in United States. Am J Gastroenterol. 1998;93:1432-1435.
24. Wang WH, Wong BC, Mukhopadhyay AK, et al. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment Pharmacol Ther. 2000;14:901-910.
25. Cayla R, Zerbib F, Talbi P, et al. Pre- and post-treatment clarythromycin resistance of Helicobacter pylori strains: a key factor of treatment failure. Gut. 1995;37:A55.
26. Tompkins DS, Perkin J, Smith C. Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. Helicobacter. 1997;2:185-187.
27. Goh KL. Update on the management of Helicobacter pylori infection, including drug-resistant organisms. J Gastroenterol Hepatol. 2002;17:482-487.
28. Dresner D, Coyle W, Nemec R, et al. Efficacy of ciprofloxacin in the eradication of Helicobacter pylori. South Med J. 1996;89:775-778.
29. Logan RP, Gummett PA, Misiewicz JJ, et al. Two-week eradication regimen for metronidazole-resistant Helicobacter pylori. Aliment Pharmacol Ther. 1993;7:149-153.
30. Labenz J, Gyenes E, Peitz U, et al. Ciprofloxacin-omeprazole combination therapy for eradication of Helicobacter pylori. Z Gastroenterol. 1991;29:143-145.
31. Forsmark CE, Wilcox CM, Cello JP, et al. Ciprofloxacin in the treatment of Helicobacter pylori in patients with gastritis and peptic ulcer. J Infect Dis. 1990;162:998-999.
32. Glupczynski Y. Antimicrobial resistance in Helicobacter pylori: a global overview. In: Hunt RH, Tytgat RH, eds. Helicobacter pylori: Basic Mechanisms to Clinical Cure 1998. Dordrecht: Kluwer Academic Publishers; 1998:398-415.
33. Sanchez IE, Saenz NG, Rincon MR, et al. Susceptibility of Helicobacter pylori to mupirocin, oxazolidones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother. 2000;46:283-285.
34. Matsuzaki K, Koyama H, Chiba A, et al. In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates. Jpn J Antibiot. 1999;52:571-584.
35. Ohara T, Goshi S, Taneike I, et al. Inhibitory action of a novel proton pump inhibitor, rapeprazole, and its thioether derivate against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter. 2001;6:125-129.
36. Gené E, Calvet X, Azagra R, et al. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther. 2003;17:1137-1144.
37. Cammarota G, Cannizzaro O, Ojetti V, et al. Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:73-77.